Status:
COMPLETED
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 1...
Eligibility Criteria
Inclusion
- Healthy
- Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30
- Signed and dated written informed consent prior to admission to the study
- Subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
Exclusion
- cardiac abnormalities
- history of asthma or severe allergic reactions
- history of alcohol or drug abuse
- use of prescription or non-prescription drugs or vitamins or herbal supplements
- history of cholecystectomy or biliary tract disease
- pregnant or nursing women
- history of allergy to the study drugs
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00411073
Start Date
December 1 2006
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Evansville, Indiana, United States, 47714